{"id":16715,"name":"Epidarex Capital","slug":"epidarex-capital","website":"https://epidarex.com","hqGeo":"Edinburgh, Scotland","stageFocus":["Pre-Seed","Seed","Series A"],"sectorTags":["Healthcare"],"excludedSectors":[],"checkSizeMin":null,"checkSizeMax":null,"thesisSummary":"Early-stage venture firm focused on building breakthrough life science companies in emerging academic hubs. The strategy emphasizes specialist life science investing outside the usual coastal US power centers.","thesisNarrative":null,"logoUrl":null,"aumUsd":250000000,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"AdoRx Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"AdoRx is developing new modulators of the adenosine pathway for the treatment of cancer.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Apellis Pharmaceuticals","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Apellis is a NASDAQ listed company developing therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Caldan Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Caldan is developing novel therapeutics targeting free fatty acid receptors for metabolic diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Clyde Biosciences","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Clyde Biosciences has developed a pioneering technology (CellOPTIQ) to rapidly evaluate cardiotoxicity risk in pharmaceuticals.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Confluence Life Sciences","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"A technology-based company focusing on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Curve Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Curve is deploying its Microcycle platform to build a pipeline of first-in-class therapeutics targeting protein-protein interactions.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"DUNAD Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Dunad is focusing on the development of next-generation small molecule therapeutics based on its highly differentiated, tuneable and targeted protein degradation technology.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Edinburgh Molecular Imaging","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"EM Imaging is a clinical phase biotechnology company with a highly novel C-Met molecular targeting technology platform.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Enterprise Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Enterprise Therapeutics is dedicated to the research and development of novel therapies for the treatment of respiratory diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Epsilogen","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Epsilogen is developing IgE-based antibody therapeutics for the treatment of cancer.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Harness Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Harness is focused on RNA-targeted upregulation of new targets to transform treatment of neurodegenerative diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Harpoon Medical, Inc.","companyUrl":null,"stage":null,"sector":"Medical Devices","investmentYear":null,"description":"Harpoon Medical is commercializing a minimally invasive, image-guided surgical tool for beating heart mitral valve repair.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Kodikaz Therapeutic Solutions","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Kodikaz is developing a novel nucleic acid based targeted delivery platform for cancer therapeutics.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Kynos Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Kynos Therapeutics is an immunemetabolic company with expertise in the kynurenine pathway.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Lario Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Lario is developing first-in-class precision medicines for epileptic and neurological disorders.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Leucid Bio","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Leucid Bio is focused on the development of new treatments for cancer utilizing engineered T cells.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Libra Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Libra Therapeutics is focused on developing novel therapeutics for neurodegenerative diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Macomics","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Macomics is developing next-generation therapies to modulate macrophages for immuno-oncology.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Mironid","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Mironid is developing proprietary drug candidates that modulate the activity of key phosphodiesterase 4 enzymes.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"NodThera","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"NodThera is developing NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Nyra Medical","companyUrl":null,"stage":null,"sector":"Medical Devices","investmentYear":null,"description":"Nyra Medical is developing a novel transcatheter mitral valve repair technology.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"RapidPulse, Inc.","companyUrl":null,"stage":null,"sector":"Medical Devices","investmentYear":null,"description":"RapidPulse is developing a novel aspiration system to treat ischemic stroke.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Ryme Medical","companyUrl":null,"stage":null,"sector":"Medical Devices","investmentYear":null,"description":"Ryme Medical is developing a novel catheter-based treatment for COPD.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Slate Bio, Inc.","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Slate Bio is developing next generation IL-2 therapies that restore the body’s natural immunological response.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"SIRAKOSS","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"SIRAKOSS is developing nano-synthetic bone graft substitutes to facilitate bone repair.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Theolytics","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Theolytics is focused on creating a step-change in the oncolytic viral therapy field.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Topas Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology","investmentYear":null,"description":"Topas is using nanoparticle technology to target autoimmune and inflammatory diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Epidarex II SPV, L.P.  (CIK 0002059414)","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"SEC Form D filing mentioning Epidarex Capital","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Transine Therapeutics","companyUrl":null,"stage":"venture-backed","sector":"biotech","investmentYear":null,"description":"Develops RNA-targeted therapies","amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":8,"partners":[{"id":54740,"name":"Rachel Haynes","title":"Operations Manager","seniority":null,"focusTags":[],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":54743,"name":"Sinclair Dunlop","title":"Managing Partner","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/sinclair-dunlop-6206083","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":54744,"name":"Anthony Voveris","title":"Chief Financial Officer","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/anthony-voveris-0a804717","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":54746,"name":"Matthew Miessau","title":"Principal","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/matthewmiessau","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":54747,"name":"Madison Grier","title":"Finance Manager","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/madison-fishwick","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":54748,"name":"Unknown","title":"GP","seniority":null,"focusTags":["Life Sciences"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":54742,"name":"Bridget Harris","title":"Operations Manager","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/bridgetharris-2017","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":54745,"name":"Lori Gough","title":"Partner","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/lori-gough-8a834914","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[{"id":1610,"name":"Epidarex Capital Fund IV","vintageYear":2019,"sizeUsd":150000000,"status":"actively investing","focusAreas":[]},{"id":1609,"name":"Epidarex Capital Fund III","vintageYear":2015,"sizeUsd":150000000,"status":"fully deployed","focusAreas":[]},{"id":1608,"name":"Epidarex Capital Fund II","vintageYear":2011,"sizeUsd":100000000,"status":"fully deployed","focusAreas":[]},{"id":1607,"name":"Epidarex Capital Fund I","vintageYear":2007,"sizeUsd":100000000,"status":"fully deployed","focusAreas":[]}],"activity":{"lastInvestmentYear":null,"investmentsThisYear":0},"activityItems":[{"kind":"fund","title":"Raised Epidarex Capital Fund IV ($150M)","url":null,"source":"fund records","occurredAt":"2019-06-30T00:00:00.000Z"},{"kind":"fund","title":"Raised Epidarex Capital Fund III ($150M)","url":null,"source":"fund records","occurredAt":"2015-06-30T00:00:00.000Z"},{"kind":"fund","title":"Raised Epidarex Capital Fund II ($100M)","url":null,"source":"fund records","occurredAt":"2011-06-30T00:00:00.000Z"},{"kind":"fund","title":"Raised Epidarex Capital Fund I ($100M)","url":null,"source":"fund records","occurredAt":"2007-06-30T00:00:00.000Z"}],"contentUpdatedAt":"2026-11-10T22:04:41.102Z","investorType":"vc","preferredApproach":"warm intro preferred","prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[{"id":11323,"name":"Mountain Pine Capital","slug":"mountain-pine-capital","logoUrl":null,"website":"https://mountainpineholdings.com/","stageFocus":["Seed"],"sectorTags":["Consumer","Healthcare","Real Estate"],"hqGeo":"Salt Lake City, UT"},{"id":12955,"name":"Jovono","slug":"jovono","logoUrl":null,"website":"https://jovono.com","stageFocus":["Seed","Series A"],"sectorTags":["Climate / Energy","Fintech","Consumer","SaaS","Healthcare"],"hqGeo":"Los Angeles, CA"},{"id":12160,"name":"Solid Ventures","slug":"solid-ventures","logoUrl":null,"website":"https://www.solidventures.vc/","stageFocus":["Seed"],"sectorTags":["Fintech","Healthcare","SaaS","Enterprise","Developer Tools","Consumer"],"hqGeo":"Austin, TX"},{"id":13026,"name":"Robin Capital","slug":"robin-capital","logoUrl":null,"website":"https://robincap.com/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["AI / ML","Fintech","SaaS","Climate / Energy","Healthcare"],"hqGeo":"Berlin, Germany"},{"id":12096,"name":"TeleHealth Ventures","slug":"telehealth-ventures","logoUrl":null,"website":"https://telehealthventures.com","stageFocus":["Seed"],"sectorTags":["Healthcare"],"hqGeo":"Austin, TX"},{"id":2457,"name":"Equilibrium Ventures","slug":"equilibrium-ventures","logoUrl":null,"website":"https://equilibrium.co/","stageFocus":["Seed"],"sectorTags":["Developer Tools","Healthcare"],"hqGeo":"Portland, OR"}],"featuredIn":[{"slug":"pre-seed","displayName":"Pre-Seed Investors","pageType":"stage"},{"slug":"seed","displayName":"Seed Investors","pageType":"stage"},{"slug":"series-a","displayName":"Series A Investors","pageType":"stage"},{"slug":"healthcare","displayName":"Healthcare Investors","pageType":"industry"}],"fundraisingResources":[{"slug":"find-right-pre-seed-investors-b2b-saas","title":"How to Find the Right Pre-Seed Investors for Your B2B SaaS Startup"},{"slug":"investormatch-mcp-server-claude-chatgpt","title":"Your Investor List Now Lives Inside Claude and ChatGPT"},{"slug":"how-to-find-investors","title":"How to Find Investors: A VC's Playbook for Founders"}],"overviewNarrative":null,"portfolioNarrative":null,"seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-11-10T22:00:15.591Z"}